Engineered immune cells show promise against tough lymphoma
NCT ID NCT04880434
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 study tested a personalized cell therapy called KTE-X19 (brexucabtagene autoleucel) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior treatments. Participants received a single infusion of their own genetically modified immune cells designed to attack the cancer. The main goal was to see how many patients had their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Academisch Medisch Centrum
Amsterdam, 1100, Netherlands
-
Advocate Aurora Health - Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068, United States
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Baylor Cancer Hospital
Dallas, Texas, 75246, United States
-
CHU de Montpellier
Montpellier, 34295, France
-
CHU de Rennes
Rennes, 35033, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Erasmus MC
Rotterdam, 3015 CE, Netherlands
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hopital Haut-Leveque
Pessac, 44035, France
-
Hospital Clinic Barcelona
Barcelona, Spain
-
Hospital Saint Louis
Paris, 75010, France
-
Hospital Universitari Vall D'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Johannes Gutenberg University Hospital-University Mainz
Mainz, 55101, Germany
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Kings College Hospital
London, SE5 9RS, United Kingdom
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Manchester Royal Infirmary
Manchester, M13 9WL, United Kingdom
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Munich University of Technology-Medical Faculty- Ethics Committee
München, 81377, Germany
-
Ohio State University
Columbus, Ohio, 43220, United States
-
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
-
Sarah Cannon - Tenessee
Nashville, Tennessee, 37203, United States
-
Sarah Cannon- Denver
Denver, Colorado, 80218, United States
-
Stanford University
Palo Alto, California, 94305, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
University California Los Angeles (UCLA)
Santa Monica, California, 90404, United States
-
University Medical Center Groningen
Groningen, 9700 RB, Netherlands
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy made from the patient's own immune cells
What this could lead to
If successful, this could provide a powerful treatment option for people with mantle cell lymphoma that has stopped responding to other therapies.
What could go wrong
This is a phase 2 trial with 95 participants, so results are not yet confirmed in larger groups. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.